루이소체 치매의 개정 진단기준 및 치료의 고찰

참고문헌 (76)

1. McKeith I, "Dementia with Lewy bodies", Lancet Neurol, 3, pp.19~28 (2004)
2. Vann Jones SA, "The prevalence and incidence of dementia with Lewy bodies : a systematic review of population and clinical studies", Psychol Med, 44, pp.673~683 (2014)
3. Tola-Arribas MA, "Prevalence of dementia and subtypes in valladolid, Northwestern Spain : The DEMINVALL Study", PLoS One, 8, pp.e77688~ (2013)
4. McKeith IG, "Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium", Neurology, 89, pp.88~100 (2017)
5. Okazaki H, "Diffuse intracytoplasmic ganglionic inclusions(Lewy type)associated with progressive dementia and quadriparesis in flexion", J Neuropathol Exp Neurol, 20, pp.237~244 (1961)
6. Holdorff B, "Friedrich Heinrich Lewy(1885-1950)and his work", J Hist Neurosci, 11, pp.19~28 (2002)
7. McKeith IG, "Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium", Neurology, 65, pp.1863~1872 (2005)
8. Walker Z, "Lewy body dementias", Lancet, 386, pp.1683~1697 (2015)
9. McKeith IG, "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies(DLB) : report of the Consortium on DLB International Workshop", Neurology, 47, pp.1113~1124 (1996)
10. McKeith IG, "Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies", Neurology, 53, pp.902~905 (1999)
11. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychaitric Association
12. Hamilton JM, "Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies", Am J Geriatr Psychiatry, 20, pp.773~781 (2012)
13. Ferman TJ, "Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer’s disease", Clin Neuropsychol, 20, pp.623~636 (2006)
14. Galvin JE, "Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score", Alzheimers Dement(Amst), 1, pp.316~324 (2015)
15. Luis CA, "Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample", Int J Geriatr Psychiatry, 14, pp.526~533 (1999)
16. Mega MS, "Dementia with Lewy bodies : reliability and validity of clinical and pathologic criteria", Neurology, 47, pp.1403~1409 (1996)
17. Bradshaw J, "Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease is qualitatively distinct", J Neurol Neurosurg Psychiatry, 75, pp.382~387 (2004)
18. Ferman TJ, "DLB fluctuations : specific features that reliably differentiate DLB from AD and normal aging", Neurology, 62, pp.181~187 (2004)
19. Lee DR, "The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia", Am J Geriatr Psychiatry, 22, pp.926~935 (2014)
20. Walker MP, "The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia", Br J Psychiatry, 177, pp.252~256 (2000)
21. Walker MP, "Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia", Neurology, 54, pp.1616~1625 (2000)
22. Harding AJ, "Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe", Brain, 125, pp.391~403 (2002)
23. Higuchi M, "Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies", Exp Neurol, 162, pp.247~256 (2000)
24. Lobotesis K, "Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD", Neurology, 56, pp.643~649 (2001)
25. Postuma RB, "MDS clinical diagnostic criteria for Parkinson’s disease", Mov Disord, 30, pp.1591~1601 (2015)
26. Ferman TJ, "Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies", Neurology, 77, pp.875~882 (2011)
27. Boeve BF, "Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder", Sleep Med, 14, pp.754~762 (2013)
28. Howell MJ, "Rapid eye movement sleep behavior disorder and neurodegenerative disease", JAMA Neurol, 72, pp.707~712 (2015)
29. Iranzo A, "Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder : study in 174 patients", PLoS One, 9, pp.e89741~ (2014)
30. Braak H, "Stages in the development of Parkinson’s disease-related pathology", Cell Tissue Res, 318, pp.121~134 (2004)
31. Boeve BF, "Idiopathic REM sleep behaviour disorder in the development of Parkinson’s disease", Lancet Neurol, 12, pp.469~482 (2013)
32. Williams SS, "Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease", J Neurol Neurosurg Psychiatry, 80, pp.667~670 (2009)
33. McKeith I, "Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study", Lancet Neurol, 6, pp.305~313 (2007)
34. Iwanaga K, "Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases", Neurology, 52, pp.1269~1271 (1999)
35. Orimo S, "Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease", Acta Neuropathol, 109, pp.583~588 (2005)
36. Yoshita M, "Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD", Neurology, 66, pp.1850~1854 (2006)
37. Yoshita M, "Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : a multicenter study", PLoS One, 10, pp.e0120540~ (2015)
38. Tiraboschi P, "(123)I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane single photon emission computed tomography and(123)I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias : a comparative study", Ann Neurol, 80, pp.368~378 (2016)
39. Jacobson AF, "Impact of medications on mIBG uptake, with specific attention to the heart: comprehensive review of the literature", J Nucl Cardiol, 22, pp.980~993 (2015)
40. McCarter SJ, "Diagnostic thresholds for quantitative REM sleep phasic burst duration, phasic and tonic muscle activity, and REM atonia index in REM sleep behavior disorder with and without comorbid obstructive sleep apnea", Sleep, 37, pp.1649~1662 (2014)
41. Frauscher B, "Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder", Sleep, 35, pp.835~847 (2012)
42. Burton EJ, "Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment : a prospective study with pathological verification of diagnosis", Brain, 132, pp.195~203 (2009)
43. O’Brien JT, "18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias", J Nucl Med, 55, pp.1959~1965 (2014)
44. Lim SM, "The 18F-FDG PET cingulate island sign and comparison to 123Ibeta-CIT SPECT for diagnosis of dementia with Lewy bodies", J Nucl Med, 50, pp.1638~1645 (2009)
45. Graff-Radford J, "Dementia with Lewy bodies : basis of cingulate island sign", Neurology, 83, pp.801~809 (2014)
46. Bonanni L, "EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up", Brain, 131, pp.690~705 (2008)
47. Petrou M, "Amyloid deposition in Parkinson’s disease and cognitive impairment : a systematic review", Mov Disord, 30, pp.928~935 (2015)
48. Abdelnour C, "Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia", Mov Disord, 31, pp.1203~1208 (2016)
49. Guella I, "α-synuclein genetic variability: a biomarker for dementia in Parkinson disease", Ann Neurol, 79, pp.991~999 (2016)
50. Stinton C, "Pharmacological management of Lewy body dementia : a systematic review and meta-analysis", Am J Psychiatry, 172, pp.731~742 (2015)
51. Wang HF, "Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis", J Neurol Neurosurg Psychiatry, 86, pp.135~143 (2015)
52. Matsunaga S, "Memantine for Lewy body disorders : systematic review and meta-analysis", Am J Geriatr Psychiatry, 23, pp.373~383 (2015)
53. Stubendorff K, "Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia : a prospective study", BMJ Open, 4, pp.e005158~ (2014)
54. Taylor JP, "New evidence on the management of Lewy body dementia", Lancet Neurol, 19, pp.157~169 (2020)
55. Goldman JG, "Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies", Mov Disord, 23, pp.2248~2250 (2008)
56. Murata M, "Adjunct zonisamide to levodopa for DLB parkinsonism : a randomized double-blind phase 2 study", Neurology, 90, pp.e664~e672 (2018)
57. Edwards K, "Efficacy and safety of galantamine in patients with dementia with Lewy bodies : a 24-week open-label study", Dement Geriatr Cogn Disord, 23, pp.401~405 (2007)
58. McKeith I, "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study", Lancet, 356, pp.2031~2036 (2000)
59. Mori E, "Donepezil for dementia with Lewy bodies: a randomized, placebocontrolled trial", Ann Neurol, 72, pp.41~52 (2012)
60. Kurlan R, "Quetiapine for agitation or psychosis in patients with dementia and parkinsonism", Neurology, 68, pp.1356~1363 (2007)
61. Cummings J, "Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial", Lancet, 383, pp.533~540 (2014)
62. Ballard C, "Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis:a phase 2, randomised, placebo-controlled, double-blind study", Lancet Neurol, 17, pp.213~222 (2018)
63. Cummings J, "Pimavanserin : potential treatment for dementia-related psychosis", J Prev Alzheimers Dis, 5, pp.253~258 (2018)
64. Aurora RN, "Best practice guide for the treatment of REM sleep behavior disorder(RBD)", J Clin Sleep Med, 6, pp.85~95 (2010)
65. Larsson V, "The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia", Int J Geriatr Psychiatry, 25, pp.1030~1038 (2010)
66. Singer W, "Acetylcholinesterase inhibition : a novel approach in the treatment of neurogenic orthostatic hypotension", J Neurol Neurosurg Psychiatry, 74, pp.1294~1298 (2003)
67. Mukherjee A, "Gut dysfunction in Parkinson’s disease", World J Gastroenterol, 22, pp.5742~5752 (2016)
68. Stocchi F, "Constipation in Parkinson’s disease", Int Rev Neurobiol, 134, pp.811~826 (2017)
69. Pedrosa Carrasco AJ, "Management of constipation in patients with Parkinson’s disease", NPJ Parkinsons Dis, 4, pp.6~ (2018)
70. Tateno F, "Lower urinary tract function in dementia with Lewy bodies(DLB)", Mov Disord, 30, pp.411~415 (2015)
71. Zesiewicz TA, "Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease", Parkinsonism Relat Disord, 21, pp.514~520 (2015)
72. Vouri SM, "Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults : a systematic review and meta-analysis", Arch Gerontol Geriatr, 69, pp.77~96 (2017)
73. Peyronnet B, "Mirabegron in patients with Parkinson disease and overactive bladder symptoms : a retrospective cohort", Parkinsonism Relat Disord, 57, pp.22~26 (2018)
74. Huh TJ, "The effectiveness of an environmental and behavioral approach to treat behavior problems in a patient with dementia with Lewy bodies : a case study", Ann Longterm Care, 16, pp.17~21 (2008)
75. Uc EY, "Phase I", II randomized trial of aerobic exercise in Parkinson disease in a community setting, 2014, pp.83, 413~425
76. Thomas AJ, "Development of assessment toolkits for improving the diagnosis of the Lewy body dementias : feasibility study within the DIAMOND Lewy study", Int J Geriatr Psychiatry, 32, pp.1280~1304 (2017)

관련 논문AI추천